Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma.

× No keyword cloud information.

10 in total

Review 1. ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors: Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal: Int J Hematol Date: 2016-01-18 Impact factor: 2.490

Review 2. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors: Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal: J Clin Exp Hematop Date: 2017

Review 3. Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors: Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal: Cancer Discov Date: 2017-01-25 Impact factor: 39.397

4. Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.

Authors: Jian Li; Jian Ouyang; Rongfu Zhou; Bing Chen; Yong Xu
Journal: Int J Clin Exp Med Date: 2015-05-15

5. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors: Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal: Mol Cancer Res Date: 2018-07-12 Impact factor: 5.852

Review 6. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.

Authors: Jing Li; Shu Zhao; Jingxuan Wang; Jingyu Chen; Wen Wen; Qingyuan Zhang
Journal: Tumour Biol Date: 2015-10-12

Review 7. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Authors: Geeta Geeta Sharma; Ines Mota; Luca Mologni; Enrico Patrucco; Carlo Gambacorti-Passerini; Roberto Chiarle
Journal: Cancers (Basel) Date: 2018-02-28 Impact factor: 6.639

Review 8. The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors: Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal: Int J Mol Sci Date: 2019-08-09 Impact factor: 5.923

9. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.

Authors: Karen L MacKenzie; Toby N Trahair; Ashleigh M Fordham; Jinhan Xie; Andrew J Gifford; Carol Wadham; Lisa T Morgan; Emily V A Mould; Mitali Fadia; Lei Zhai; Hassina Massudi; Zara S Ali; Glenn M Marshall; Robyn E Lukeis; Jamie I Fletcher
Journal: Br J Cancer Date: 2020-07-20 Impact factor: 7.640

10. Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis.

Authors: Xiaopeng Wang; Shixia Wang
Journal: Transl Cancer Res Date: 2021-12 Impact factor: 1.241

10 in total